(vianews) - the market ended the session with gensight biologics (sight.pa) rising 12.64% to €0.61 on wednesday, following the last session's upward trend. cac 40 jumped 0.69% to €7,034.16, after three sequential sessions in a row of losses, on what was a somewhat bullish trend trading session today.
gensight biologics's last close was €0.54, 86.13% under its 52-week high of €3.88.
about gensight biologics
gensight biologics s.a., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. the company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. its lead product candidates include lumevoq (gs010), a recombinant aav2-based gene therapy, which is in phase iii clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated nd4 gene; and gs030, which is in phase i/ii clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. the company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. the company was incorporated in 2012 and is headquartered in paris, france.
earnings per share
as for profitability, gensight biologics has a trailing twelve months eps of €-0.63.
yearly top and bottom value
gensight biologics's stock is valued at €0.61 at 21:38 est, way below its 52-week high of €3.88 and way higher than its 52-week low of €0.38.
revenue growth
year-on-year quarterly revenue growth declined by 36.1%, now sitting on 3.33m for the twelve trailing months.
more news about gensight biologics (sight.pa).